
Market volatility threatens Evonik IPO
The RAG Foundation, which owns a majority stake in CVC-backed German chemicals maker Evonik, could cancel the company's IPO in light of the current market environment.
"The developments on the financial markets since the end of May have resulted in a mounting uncertainty whether proceeds can be achieved that reflect Evonik's inherent value," the Foundation said in a statement.
"Both the Board of Trustees and the Board of Executives share the view that these issues call for clarification, as otherwise the IPO of Evonik will have to be cancelled," the statement continued.
RAG's board will hold meetings with investors this week to inform its decision, which will be taken by the end of June.
Evonik confirmed at the end of May that it was looking to float on the Prime Standard segment of the Frankfurt stock exchange. Evonik's owners are reportedly aiming for a valuation in the region of €15bn, which is understood to be considered too steep by investors.
CVC owns a 25% stake in the business, which it acquired for €2.4bn in 2008. The majority is owned by the RAG Foundation, which was set up by the government in 2007 to ease the social costs and liabilities associated with the ending of subsidised coal mining in 2018.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater